The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C

The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C

Direct-acting antivirals (DAAs) have been introduced for the treatment of hepatitis C virus, and the sustained virological response rate after DAAs was reported to be over 95％. Because of the high sustained virological response rate, the risk of hepatocellular carcinoma (HCC) was expected to be redu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatoma research 2020-03, Vol.2020 (3), p.15-23
Hauptverfasser: Yoo, Sun Hong, Kwon, Jung Hyun
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 23
container_issue 3
container_start_page 15
container_title Hepatoma research
container_volume 2020
creator Yoo, Sun Hong
Kwon, Jung Hyun
description Direct-acting antivirals (DAAs) have been introduced for the treatment of hepatitis C virus, and the sustained virological response rate after DAAs was reported to be over 95％. Because of the high sustained virological response rate, the risk of hepatocellular carcinoma (HCC) was expected to be reduced. However, an unexpected high risk of HCC recurrence after DAA treatment was reported, and thus the dispute about the association of DAA and HCC arose. The present article reviews the interplay between DAAs and HCC.
doi_str_mv 10.20517/2394-5079.2019.49
format Article
fullrecord <record><control><sourceid>wanfang_jour_cross</sourceid><recordid>TN_cdi_wanfang_journals_gayj_e202003003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>gayj_e202003003</wanfj_id><sourcerecordid>gayj_e202003003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2383-b63912b35b4bafd471bccb861a54202b6ccab03afcef8d34496365ae6cdd1c023</originalsourceid><addsrcrecordid>eNo1kE1LAzEQhoMoWLR_wFNunrbme5ujFL-g4KWew2Q226ZssyW7tfTfm1qFgXmHeecdeAh54GwmmOb1k5BWVZrVtszczpS9IhOhtKqEFuy66P_9LZkOw5YxJqzhsuYT4lebQGMaQ953cKI-jMcQEm1iDjhWgGNMawppjN8xQzcU2dBN2MPYY-i6QweZImSMqd9ByaG4yX2KePHEMQ50cU9u2nIapn_9jny9vqwW79Xy8-1j8bysUMi5rLyRlgsvtVce2kbV3CP6ueGglWDCG0TwTEKLoZ03UilrpNEQDDYNRybkHXm85B4htZDWbtsfciof3RpOWxdKCGOyVHGKixNzPww5tG6f4w7yyXHmfpG6MzJ3RubOSJ2y8gc8YmqX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Yoo, Sun Hong ; Kwon, Jung Hyun</creator><creatorcontrib>Yoo, Sun Hong ; Kwon, Jung Hyun</creatorcontrib><description>Direct-acting antivirals (DAAs) have been introduced for the treatment of hepatitis C virus, and the sustained virological response rate after DAAs was reported to be over 95％. Because of the high sustained virological response rate, the risk of hepatocellular carcinoma (HCC) was expected to be reduced. However, an unexpected high risk of HCC recurrence after DAA treatment was reported, and thus the dispute about the association of DAA and HCC arose. The present article reviews the interplay between DAAs and HCC.</description><identifier>ISSN: 2394-5079</identifier><identifier>EISSN: 2454-2520</identifier><identifier>DOI: 10.20517/2394-5079.2019.49</identifier><language>eng</language><publisher>Department of Internal Medicine, Catholic University Liver Research Center, The Catholic University of Korea, Seoul 06591, Korea</publisher><ispartof>Hepatoma research, 2020-03, Vol.2020 (3), p.15-23</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2383-b63912b35b4bafd471bccb861a54202b6ccab03afcef8d34496365ae6cdd1c023</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/gayj-e/gayj-e.jpg</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Yoo, Sun Hong</creatorcontrib><creatorcontrib>Kwon, Jung Hyun</creatorcontrib><title>The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C</title><title>Hepatoma research</title><description>Direct-acting antivirals (DAAs) have been introduced for the treatment of hepatitis C virus, and the sustained virological response rate after DAAs was reported to be over 95％. Because of the high sustained virological response rate, the risk of hepatocellular carcinoma (HCC) was expected to be reduced. However, an unexpected high risk of HCC recurrence after DAA treatment was reported, and thus the dispute about the association of DAA and HCC arose. The present article reviews the interplay between DAAs and HCC.</description><issn>2394-5079</issn><issn>2454-2520</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo1kE1LAzEQhoMoWLR_wFNunrbme5ujFL-g4KWew2Q226ZssyW7tfTfm1qFgXmHeecdeAh54GwmmOb1k5BWVZrVtszczpS9IhOhtKqEFuy66P_9LZkOw5YxJqzhsuYT4lebQGMaQ953cKI-jMcQEm1iDjhWgGNMawppjN8xQzcU2dBN2MPYY-i6QweZImSMqd9ByaG4yX2KePHEMQ50cU9u2nIapn_9jny9vqwW79Xy8-1j8bysUMi5rLyRlgsvtVce2kbV3CP6ueGglWDCG0TwTEKLoZ03UilrpNEQDDYNRybkHXm85B4htZDWbtsfciof3RpOWxdKCGOyVHGKixNzPww5tG6f4w7yyXHmfpG6MzJ3RubOSJ2y8gc8YmqX</recordid><startdate>20200306</startdate><enddate>20200306</enddate><creator>Yoo, Sun Hong</creator><creator>Kwon, Jung Hyun</creator><general>Department of Internal Medicine, Catholic University Liver Research Center, The Catholic University of Korea, Seoul 06591, Korea</general><scope>AAYXX</scope><scope>CITATION</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>20200306</creationdate><title>The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C</title><author>Yoo, Sun Hong ; Kwon, Jung Hyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2383-b63912b35b4bafd471bccb861a54202b6ccab03afcef8d34496365ae6cdd1c023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Yoo, Sun Hong</creatorcontrib><creatorcontrib>Kwon, Jung Hyun</creatorcontrib><collection>CrossRef</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Hepatoma research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoo, Sun Hong</au><au>Kwon, Jung Hyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C</atitle><jtitle>Hepatoma research</jtitle><date>2020-03-06</date><risdate>2020</risdate><volume>2020</volume><issue>3</issue><spage>15</spage><epage>23</epage><pages>15-23</pages><issn>2394-5079</issn><eissn>2454-2520</eissn><abstract>Direct-acting antivirals (DAAs) have been introduced for the treatment of hepatitis C virus, and the sustained virological response rate after DAAs was reported to be over 95％. Because of the high sustained virological response rate, the risk of hepatocellular carcinoma (HCC) was expected to be reduced. However, an unexpected high risk of HCC recurrence after DAA treatment was reported, and thus the dispute about the association of DAA and HCC arose. The present article reviews the interplay between DAAs and HCC.</abstract><pub>Department of Internal Medicine, Catholic University Liver Research Center, The Catholic University of Korea, Seoul 06591, Korea</pub><doi>10.20517/2394-5079.2019.49</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2394-5079
ispartof Hepatoma research, 2020-03, Vol.2020 (3), p.15-23
issn 2394-5079
2454-2520
language eng
recordid cdi_wanfang_journals_gayj_e202003003
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A57%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20interplay%20between%20direct-acting%20antivirals%20and%20hepatocellular%20carcinoma%20in%20chronic%20hepatitis%20C&rft.jtitle=Hepatoma%20research&rft.au=Yoo,%20Sun%20Hong&rft.date=2020-03-06&rft.volume=2020&rft.issue=3&rft.spage=15&rft.epage=23&rft.pages=15-23&rft.issn=2394-5079&rft.eissn=2454-2520&rft_id=info:doi/10.20517/2394-5079.2019.49&rft_dat=%3Cwanfang_jour_cross%3Egayj_e202003003%3C/wanfang_jour_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_wanfj_id=gayj_e202003003&rfr_iscdi=true